Literature DB >> 11554942

Mild bleeding diathesis in a boy with combined severe haemophilia B (C(10400)-->T) and heterozygous factor V Leiden.

F Vianello1, D Belvini, F Dal Bello, G Tagariello, E Zanon, A M Lombardi, P Zerbinati, A Girolami.   

Abstract

Haemophilia B patients with factor IX (FIX) activity < 1% are usually characterized by severe bleeding episodes early in life. We report a case of sporadic severe haemophilia B, clinically characterized by mild bleeding diathesis. The presence of anamnestic thrombophlebitis in the patient's mother prompted us to investigate a possible associated hypercoagulable condition. Resistance to activated protein C due to factor V R506Q mutation was present in the mother and in the propositus, in the homozygous and heterozygous form, respectively. Molecular analysis of the FIX gene led to the identification of a nonsense mutation resulting in a stop codon at position 50, previously described and usually responsible for a severe pattern of haemophilia B. The implications of this unusual association are discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11554942     DOI: 10.1046/j.1365-2516.2001.00551.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  6 in total

1.  Design and characterization of an APC-specific serpin for the treatment of hemophilia.

Authors:  Stéphanie G I Polderdijk; Ty E Adams; Lacramioara Ivanciu; Rodney M Camire; Trevor P Baglin; James A Huntington
Journal:  Blood       Date:  2016-10-27       Impact factor: 22.113

2.  Discrepant ratios of arterial versus venous thrombosis in hemophilia A as compared with hemophilia B.

Authors:  Antonio Girolami; Irene Bertozzi; Giulia Berti de Marinis; Valentina Tasinato; Luisa Sambado
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

3.  Coagulation disorders seen through the window of molecular biology.

Authors:  Kanjaksha Ghosh
Journal:  Indian J Hum Genet       Date:  2007-09

4.  Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C.

Authors:  Miao Jiang; Fei Yang; Yizhi Jiang; Lu Cheng; Jingjing Han; Jiawei Yi; Guige Zhang; Zhenni Ma; Lijuan Cao; Bin Zuo; Lixia Zhou; Lulu Huang; Siying Niu; Zhisong Xia; Xuefeng Zhou; Xia Bai; Naomi L Esmon; Changgeng Ruan; Lijun Xia; Yue Han; Charles T Esmon; Depei Wu; Jun Xu
Journal:  Blood Adv       Date:  2022-06-14

Review 5.  Non-factor therapies for bleeding disorders: A primer for the general haematologist.

Authors:  Dawn Swan; Johnny Mahlangu; Jecko Thachil
Journal:  EJHaem       Date:  2022-04-28

6.  Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia.

Authors:  Xiao-Yan Zhao; Andreas Wilmen; Dongli Wang; Xinquan Wang; Maxine Bauzon; Ji-Yun Kim; Lars Linden; Liang Li; Ursula Egner; Tobias Marquardt; Dieter Moosmayer; Jan Tebbe; Julian Marius Glück; Philipp Ellinger; Kirk McLean; Shujun Yuan; Subramanian Yegneswaran; Xiaoqiao Jiang; Vince Evans; Jian-Ming Gu; Doug Schneider; Ying Zhu; Yifan Xu; Cornell Mallari; Ashley Hesslein; Yan Wang; Nicole Schmidt; Katrin Gutberlet; Christine Ruehl-Fehlert; Alexius Freyberger; Terry Hermiston; Chandra Patel; Derek Sim; Laurent O Mosnier; Volker Laux
Journal:  Nat Commun       Date:  2020-06-12       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.